| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | -100.0% | -100.0% |
| R&D Expense | $49.2M | +21.6% | +32.2% |
| SG&A Expense | $10.9M | +9.0% | +14.9% |
| Operating Income | -$60.1M | -29.4% | -19.0% |
| Net Income | -$57.5M | -32.4% | -22.0% |
| EPS (Basic) | -$0.65 | -30.0% | +16.7% |
| EPS (Diluted) | -$0.65 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $272.6M | +89.5% | +75.3% |
| Current Assets | $279.9M | +0.9% | +14.7% |
| Total Assets | $299.4M | +1.0% | +16.5% |
| Current Liabilities | $31.4M | +37.4% | -20.4% |
| Total Liabilities | $35.5M | +31.2% | -15.6% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$143.0M | — | — |
| Capital Expenditures | $5.7M | — | — |
| Investing Cash Flow | $64.8M | — | — |
| Financing Cash Flow | $207.6M | — | — |
| Free Cash Flow | -$148.7M | — | — |
| -30.0% |
| +16.7% |
| $263.9M |
| -2.0% |
| +22.8% |